ArticleProceedings of the National Academy of Sciences of the United States of America2009
An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Conformation-specific Synthetic Antibodies Discriminate Multiple Functional States of the Ion Channel CorA.Journal of molecular biology · 2023Article
- Radiolabeled Gold Nanoseeds Decorated with Substance P Peptides: Synthesis, Characterization and In Vitro Evaluation in Glioblastoma Cellular Models.International journal of molecular sciences · 2022Article
- An engineered ultra-high affinity Fab-Protein G pair enables a modular antibody platform with multifunctional capability.Protein science : a publication of the Protein Society · 2020Article
- Improving cellular uptake of therapeutic entities through interaction with components of cell membrane.Drug delivery · 2019Review
- Targeted rescue of cancer-associated IDH1 mutant activity using an engineered synthetic antibody.Scientific reports · 2017Article
- Getting across the cell membrane: an overview for small molecules, peptides, and proteins.Methods in molecular biology (Clifton, N.J.) · 2015Review
- New type of BACE1 siRNA delivery to cells.Medical science monitor : international medical journal of experimental and clinical research · 2014Article
- Synthetic biology in mammalian cells: next generation research tools and therapeutics.Nature reviews. Molecular cell biology · 2014Review
- Green fluorescent protein fused to peptide agonists of two dissimilar G protein-coupled receptors: novel ligands of the bradykinin B2 (rhodopsin family) receptor and parathyroid hormone PTH1 (secretin family) receptor.Pharmacology research & perspectives · 2013Article
- Generating conformation-specific synthetic antibodies to trap proteins in selected functional states.Methods (San Diego, Calif.) · 2013Article
- Cellular uptake mechanisms and endosomal trafficking of supercharged proteins.Chemistry & biology · 2012Article
- Boronate-mediated biologic delivery.Journal of the American Chemical Society · 2012Article
- Substance P derivatives as versatile tools for specific delivery of various types of biomolecular cargo.Bioconjugate chemistry · 2012Article
- Allosteric control of ligand-binding affinity using engineered conformation-specific effector proteins.Nature structural & molecular biology · 2011Article
- Beyond natural antibodies: the power of in vitro display technologies.Nature biotechnology · 2011Article
- Characterization of engineered actin binding proteins that control filament assembly and structure.PloS one · 2010Article
- Potent delivery of functional proteins into Mammalian cells in vitro and in vivo using a supercharged protein.ACS chemical biology · 2010Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
We have developed and tested a robust delivery method for the transport of proteins to the cytoplasm of mammalian cells without compromising the integrity of the cell membrane. This receptor-mediated delivery (RMD) technology utilizes a variant of substance P (SP), a neuropeptide that is rapidly internalized upon interaction with the neurokinin-1 receptor (NK1R). Cargos in the form of synthetic antibody fragments (sABs) were conjugated to the engineered SP variant (SPv) and efficiently internalized by NK1R-expressing cells. The sABs used here were generated to bind specific conformational forms of actin. The internalized proteins appear to escape the endosome and retain their binding activity within the cells as demonstrated by co-localization with the actin cytoskeleton. Further, since the NK1R is over-expressed in many cancers, SPv-mediated delivery provides a highly specific method for therapeutic utilization of affinity reagents targeting intracellular processes in diseased tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.